Journal of Virology, December 1998, p. 10165-10170, Vol. 72, No. 12
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
andDepartment of Medicine1 and Immunogenetics and Transplantation Laboratory, Department of Surgery,2 School of Medicine, University of California, San Francisco, San Francisco, California 94143-1270
Received 14 July 1998/Accepted 1 September 1998
| |
ABSTRACT |
|---|
|
|
|---|
CD8+ T cells from human immunodeficiency virus (HIV)-infected individuals can suppress HIV replication in cultured CD4+ cells by a noncytotoxic mechanism. Efficient suppression of HIV replication (>90% reduction) does not require HLA class I or class II histocompatibility between the effector CD8+ T cells and the infected target CD4+ T cells. However, maximal control of HIV production occurs when the CD8+ effector cells and CD4+ target cells are syngeneic. In some cases, more than 20-fold fewer syngeneic CD8+ T cells were required to achieve the same degree of HIV inhibition as HLA-mismatched CD8+ T cells. The increased antiviral activity seen in the syngeneic setting did not map exclusively to either the HLA class I or class II locus. These findings suggest that genetic compatibility (potentially, but not necessarily, at the HLA class I and class II loci) regulates CD8+ T-cell noncytotoxic antiviral activity against infected CD4+ T cells.
| |
INTRODUCTION |
|---|
|
|
|---|
CD8+ T cells from healthy human immunodeficiency virus (HIV)-infected individuals can suppress HIV replication in cultured CD4+ T cells without any apparent killing of infected cells (16, 28). This noncytotoxic CD8+-cell antiviral response is detected by a reduction in HIV p24 antigen and/or reverse transcriptase (RT) levels in culture fluids upon mixing CD8+ T cells with the infected target CD4+ T cells. This cellular immune response can suppress replication of HIV type 1 (HIV-1), HIV-2, and simian immunodeficiency virus (references 16 and 29 and unpublished observations) and has been observed in several species of nonhuman primates (2, 6, 8, 13, 23).
Unlike the antigen-specific cytotoxic mechanism of HLA class I-restricted CD8+ cytotoxic T lymphocytes (CTL), the CD8+-T-cell noncytotoxic anti-HIV activity does not appear to require HLA compatibility to effectively control HIV replication (17). Although initial evidence suggested a more efficient control of HIV in autologous settings (27, 28), a number of laboratories have shown that CD8+ cells (polyclonal or clonal) can efficiently inhibit HIV replication (by >90%) in heterologous peripheral blood mononuclear cells (PBMC) or CD4+ T cells (1, 3, 16, 20, 26, 28, 29). Importantly, the antiviral activity in these heterologous systems does not seem to be dependent on alloreactivity between the CD4+ target cells and the CD8+ effector cells (29).
To determine if HLA genetics regulate this type of cellular anti-HIV response, we investigated the HLA compatibility requirements for efficient control of HIV replication by CD8+ T cells. The results suggest that the extent of this antiviral CD8+-T-cell noncytotoxic response is dependent on the genetic relatedness between the effector and target cells, but not necessarily on HLA class I or class II determinants.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Subjects. Heparinized peripheral blood samples were obtained by venipuncture from HIV-1-seropositive and -seronegative donors. Among these, two pairs of identical twins, discordant for HIV infection, were studied. The HIV-infected twins were clinically healthy, with CD4+-T-cell counts of around 400/µl (14 to 16%) in one case and just over 300/µl (24 to 26%) in the other. Both individuals have been infected for over 10 years. In addition, cells from four other long-term-asymptomatic HIV-infected subjects were studied. Their CD4+-T-cell counts ranged from 319 to 940 cells/µl (23 to 36%). Blood samples from HIV-seronegative donors were obtained from laboratory volunteers or were provided by Irwin Memorial Blood Centers (San Francisco, Calif.). The study received the approval of the Committee on Human Research, University of California, San Francisco.
Assay for CD8+-cell noncytotoxic antiviral
activity.
Purified CD4+ cells isolated from uninfected
(or, in some cases, infected) blood donors were stimulated and acutely
infected with HIV-1 as described previously (20). In brief,
the CD4+ cells, purified with anti-CD4 immunomagnetic beads
(Dynal, Lake Success, N.Y.), were cultured for 3 days with 3 µg of
phytohemagglutinin (PHA) (Sigma Chemical Co., St. Louis, Mo.)/ml in
RPMI 1640 medium containing 2 mM glutamine, 1% antibiotics (100 U of
penicillin/ml, 100 µg of streptomycin/ml), 10% heat-inactivated
(56°C; 30 min) fetal calf serum, and 100 U of human recombinant
interleukin 2 (Collaborative Research, Bedford, Mass.)/ml. In each
case, the purity of the CD4+-cell populations was 95% or
greater and >95% were CD3+ as assessed by flow cytometric
analysis (15). The stimulated cells were then washed and
treated with Polybrene (2 µg/ml for 30 min at 37°C) and
subsequently acutely infected with 104 50% tissue culture
infective doses of HIV-1SF33. This virus is a highly
cytopathic strain (25) and is not sensitive to the antiviral
effects of
-chemokines (18). After 1 h of incubation with virus at 37°C, the cells were washed and resuspended in the RPMI
1640 growth medium. This method of infection routinely yields 15 to
35% HIV antigen-positive cells as detected by immunofluorescence at
the peak of HIV replication (5 to 7 days) (20).
HLA typing for class I and class II antigens. The subjects' HLA class I phenotypes were determined by serologic or molecular methods. Class I antigens were detected by the use of the standard microlymphocytotoxicity technique (11), while the genetic alleles were determined by DNA-typing techniques, using sequence-specific primers (5, 21). The HLA class II phenotype was determined by similar molecular methods.
| |
RESULTS |
|---|
|
|
|---|
HLA compatibility requirements: HIV-discordant identical twins. (i) Genetic similarity confers maximal suppression of HIV. The relative degree of antiviral activity of CD8+ T cells from healthy HIV-infected individuals was assessed by using experimentally infected CD4+ T cells of differing genetic relatedness to the effector cells (Table 1). We first analyzed HLA compatibility requirements with CD4+ cells from seronegative donors as targets and CD8+ cells from two pairs of HIV-discordant monozygotic twins. Thus, in one case, PHA-stimulated CD8+ T cells from subject T1A were cocultured at various input ratios with HIV-1SF33-infected CD4+ T cells that were syngeneic (from subject T1A's uninfected twin, subject T1B), HLA mismatched in the class I and II loci, or mismatched in only the class I or class II locus. The highest degree of HIV suppression was observed when syngeneic infected target CD4+ T cells were used (Fig. 1A). Almost-complete inhibition of HIV replication (97% reduction) was seen at the lowest CD8+-cell/CD4+-cell ratio tested (0.25). In contrast, in cultures of completely mismatched cells, only half the suppression of HIV replication (48%) occurred at the same CD8+-cell/CD4+-cell ratio (0.25). From a different perspective, even at the CD8+-cell/CD4+-cell ratio of 2.0, HIV suppression in HLA class I- and class II-mismatched CD4+ T cells did not reach the level of that observed when syngeneic target cells were used at the CD8+/CD4+ cell ratio of 0.25 (88 versus 99%, respectively). Thus, greater than eightfold more CD8+ T cells were required to inhibit HIV replication in HLA-unrelated CD4+ T cells than in HLA-identical CD4+ T cells.
|
|
(ii) Genetic regulatory effect is not dependent on in vitro activation of CD8+ cells. To further evaluate the extent to which HLA genetics regulate CD8+-cell antiviral responses, analogous experiments were performed with CD8+ cells that were not previously mitogen activated (as opposed to the experiments described above). As with mitogen-stimulated CD8+ cells, the most efficient control by unstimulated CD8+ cells was observed against syngeneic CD4+ cells (Fig. 1C). Unstimulated CD8+ cells showed less antiviral activity against target cells that were mismatched at class I, class II, or both loci.
Results with CD4+ target cells from HIV-infected subjects. In order to further establish the significance of these findings, CD8+ cells from four additional HIV-infected subjects were evaluated. Because no other twins discordant for HIV infection were available, syngeneic target cells could only be obtained by using autologous CD4+ cells. Thus, CD4+ cells from HIV-infected subjects of different HLA relatedness were experimentally infected with HIV-1 and used as target cells (Table 2). Typically, endogenous virus is not released into culture at appreciable levels until 12 days poststimulation (unpublished observations). It is, therefore, unlikely that endogenous virus contributes much to the total peak HIV replication measured (on day 6 or 9) in these cultures. Reciprocal pairings of effector and target cells were performed to control for possible variations in the replicative capacity of the different CD4+-cell populations used.
|
80%
suppression was not observed until a
CD8+-cell/CD4+-cell ratio of 0.5 and 1.0, respectively, was reached. The lowest extent of
CD8+-cell-mediated suppression occurred when the effector
and target cells were completely unrelated in both the class I and
class II loci (e.g., S9 CD4+ cells). In this case, 80%
suppression of HIV replication occurred at the
CD8+-cell/CD4+-cell ratio of 2.0 (data not
shown). These results indicated that about 20-fold more
CD8+ cells were required to achieve the same amount
of suppression as that seen in the syngeneic setting.
|
Analysis of reciprocal pairings among subjects' effector and target cells. With the experimental data shown in Fig. 2, analysis of reciprocal pairings of effector and target cells (including mismatches at class I, class II, or both loci) revealed no consistent pattern of genetic regulation (Fig. 3). The CD8+-cell antiviral activity in one direction was usually markedly different than that in the opposite direction, even when the data was standardized for the intrinsic (maximal) level of an individual's CD8+-cell antiviral activity (i.e., that seen in the syngeneic setting). This finding was made even though three pairings involved the same target cells (S6 CD4+ cells). For example, in one case, S6 CD8+ cells controlled HIV replication in the S7 mismatched CD4+ cells an average of fivefold more than S7 CD8+ cells controlled virus production in S6 CD4+ cells. In the two other reciprocal cases involving S6 cells (with T1A and S9), the opposite was true (about seven- and twofold less suppression, respectively).
|
| |
DISCUSSION |
|---|
|
|
|---|
CD8+ T cells from HIV-infected individuals suppress HIV replication in acutely infected CD4+ T cells (reviewed in reference 16). The present studies indicate that maximal CD8+-cell suppression of HIV replication in culture is achieved when the infected CD4+ target cells and the effector CD8+ T cells are syngeneic, and thus share the same HLA class I and II genotype. Mismatches in the class I as well as the class II locus resulted in less efficient control of HIV by antiviral CD8+ T cells, but possibly better than that in the completely mismatched setting. The results suggest that genetic relatedness between CD8+ cells and CD4+ cells influences the extent of CD8+-cell anti-HIV activity and that, unlike classic CD8+-cell cytolytic activity, this response is not class I restricted.
Of six different HIV-infected subjects' CD8+ cells
studied, nearly all suppressed HIV replication better in syngeneic
infected CD4+ cells than in any of the mismatched
CD4+-cell settings (Fig. 1 and 2). The increased
suppressing activity in the syngeneic setting was reflected by a higher
percent suppression of HIV at various
CD8+-cell/CD4+-cell ratios (most prominently at
the low ratios) or by a lower number of CD8+ cells required
to achieve a certain level of HIV suppression (i.e., 4- to >20-fold
fewer CD8+ cells needed to suppress HIV by
80%). This
genetic compatibility effect was independent of whether the target
cells used were from HIV-seropositive (Fig. 2) or -seronegative (Fig.
1) donors, and it does not appear to be due to differences in
CD4+-cell HIV-replicative capacity or sensitivity to
CD8+-cell-mediated suppression. While totally mismatched
effector and target cells may have resulted in the smallest amount of
HIV suppression, we cannot conclude that relatedness at class I or class II conferred a statistically significant increase in antiviral activity. Furthermore, no consistent difference in the extent of
suppression was seen between class I-related and class II-related settings, albeit the number of shared alleles was never more than two
and in several cases was only one (Fig. 1 and 2).
The similar pattern of suppressing activity seen when freshly isolated (non-exogenously stimulated) CD8+ cells were used suggests that this apparent genetic control of noncytolytic antiviral activity is not dependent on mitogen stimulation (Fig. 1C). This finding may be the consequence of the highly activated nature of CD8+ T cells in HIV-infected individuals (15).
This type of CD8+-cell noncytolytic anti-HIV response
appears to result from a block in viral transcription (16,
19). The findings of this study imply that genetic compatibility
in some way either enhances this mechanism for controlling HIV or
provides for the activity of an additional type of antiviral mechanism that is genetically restricted. Both possibilities would be consistent with the observation that, even if the effector and target cells are
totally HLA mismatched, efficient HIV suppression can be achieved if a
high enough CD8+ effector cell input is used (Fig. 1 and
2). Since a
-chemokine-insensitive HIV isolate was used in the
present study, involvement of
-chemokine-mediated antiviral
effects (7) are not likely. Furthermore, because CD8+ T cells do not produce type 1 interferons (unpublished
observations) and gamma interferon does not have anti-HIV activity in
HIV-infected CD4+ T cells (20a), interferons are
not likely to be responsible for the higher suppressing activity seen
in HLA-matched settings.
Cytotoxic activity is an obvious antiviral mechanism worth
consideration. Many studies addressing this issue provide evidence that
cytotoxicity is not responsible for the control of HIV replication in
the autologous (or heterologous) systems used to study CD8+
cell suppression of HIV production. Infected cells are not eliminated by the CD8+ cells (9, 14, 19, 28, 30), nor is
there cytolytic release of chromium-51 from autologous target
cells (22, 26). In addition, the low
CD8+-cell/CD4+-cell ratios (0.25 in
the syngeneic setting) required to block HIV replication (
90%
suppression) are well below that seen for polyclonal or even clonal CTL
(12). Even if only 10% of the CD4+ cells were
initially infected in our assays, the actual effector/target cell ratio
would be 2.5 if every CD8+ cell was an effector cell, which
was likely not the case. Finally, HIV-specific CD8+ CTL are
exclusively class I restricted (12). The suppressing activity we observed was not genetically restricted at high
CD8+-cell inputs, nor was it strictly class I restricted at
lower inputs. In four of four cases in which the CD8+ cells
and CD4+ cells were mismatched at class I (sharing one or
two alleles at class II), a higher degree of suppression was observed
relative to the completely mismatched setting (Fig. 1 and 2). Further
analysis is required to determine specifically what role, if any, is
played by class I or class II antigens in the increased suppressing
activity seen in the syngeneic setting.
Another possible explanation for the present findings is that the lower activity seen in the HLA-mismatched cases reflects allostimulatory signals that result in either up-regulation of HIV replication in the target CD4+ cells (hence, less apparent suppression) or down-regulation of CD8+-cell antiviral activity. Allogeneic activity can involve either class I or class II antigens (24) and thus would not necessarily be restricted to either locus. The findings of Bruhl et al. (4) showing that allogeneic stimulation of CD8+ cells can induce HIV-suppressive activity would seem to argue against the latter possibility. Preliminary studies addressing the former possibility indicate that a slight enhancement of HIV replication can occur upon exposure of the infected CD4+ cells to a high input of allogeneic CD8+ cells that lack antiviral activity, but not to the extent that could explain the difference in CD8+-cell activity we have observed (unpublished observations). In addition, the results from the reciprocal pairings (Fig. 3) showing marked differences in the extent of suppression from one direction to the other are not entirely consistent with allogeneic recognition being the sole regulating factor, since in all the cases that involved nonsyngeneic matches, most or all of the HLA alleles were allogeneic.
In summary, HIV-infected individuals possess CD8+ cells that can efficiently suppress HIV replication in HLA-unrelated CD4+ lymphocytes. However, control of HIV production is maximal in a syngeneic setting regardless of whether or not the CD8+ cells are mitogen stimulated. This control does not appear to be strictly restricted to either the class I or class II locus, leaving a question as to whether a nonclassical antigen recognition process is involved. The findings suggest that many of the heterologous-cell assay systems employed to measure CD8+-T-cell-mediated noncytotoxic suppression of HIV replication are likely underestimating the relative degree of potential antiviral activity in the host. Furthermore, these studies emphasize the importance of considering the genetic relatedness between the effector and target cells when studying mechanistic issues and when quantitating and comparing noncytotoxic CD8+-T-cell antiviral activity. A better understanding of the regulation of this CD8+-T-cell anti-HIV activity could lead to improving or at least maintaining this antiviral response.
| |
ACKNOWLEDGMENTS |
|---|
These studies were funded by a grant from the NIH (RO1 AI30350) and the Histocompatibility Fund (M.R.G.). C.E.M. was supported in part by the University of California, San Francisco, AIDS Clinical Research Center (funded by the University of California Universitywide AIDS Research Program).
We thank Roland Orque and Susan Ridha for their technical assistance and Christine Beglinger and Ann Murai for help in preparation of the manuscript.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Medicine, School of Medicine, University of California, San Francisco, San Francisco, CA 94143-1270. Phone: (415) 476-4071. Fax: (415) 476-8365. E-mail: jalevy{at}itsa.ucsf.edu.
Present address: Xoma Corporation, Berkeley, CA 94170.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Barker, T. D., D. Weissman, J. A. Daucher, K. M. Roche, and A. S. Fauci. 1996. Identification of multiple and distinct CD8+ T cell suppressor activities. J. Immunol. 156:4476-4483[Abstract]. |
| 2. | Blackbourn, D. J., C. P. Locher, B. Ramachandran, S. W. Barnett, K. K. Murthy, K. D. Carey, K. M. Brasky, and J. A. Levy. 1997. CD8+ cells from HIV-2-infected baboons control HIV replication. AIDS 11:737-746[Medline]. |
| 3. | Brinchmann, J. E., G. Gaudernack, and F. Vartdal. 1990. CD8+ T cells inhibit HIV replication in naturally infected CD4+ T cells: evidence for a soluble inhibitor. J. Immunol. 144:2961-2966[Abstract]. |
| 4. | Bruhl, P., A. Kerschbaum, K. Zimmermann, M. M. Eibl, and J. W. Mannhalter. 1996. Allostimulated lymphocytes inhibit replication of HIV type 1. AIDS Res. Hum. Retroviruses 12:31-37[Medline]. |
| 5. | Bunce, M., C. J. Taylor, and K. W. Welsh. 1993. Rapid HLA-DQB typing by eight polymerase chain reaction amplifications with sequence specific primers (PCR-SSP). Hum. Immunol. 37:201-206[Medline]. |
| 6. | Castro, B. A., C. M. Walker, J. W. Eichberg, and J. A. Levy. 1991. Suppression of human immunodeficiency virus replication by CD8+ cells from infected and uninfected chimpanzees. Cell. Immunol. 132:246-255[Medline]. |
| 7. |
Cocchi, F.,
A. L. DeVico,
A. Garzino-Demo,
S. K. Arya,
R. C. Gallo, and P. Lusso.
1995.
Identification of RANTES, MIP-1alpha, and MIP-1beta as the major HIV-suppressive factors produced by CD8+ T cells.
Science
270:1811-1815 |
| 8. |
Ennen, J.,
H. Findeklee,
M. T. Dittmar,
S. Norley,
M. Ernst, and R. Kurth.
1994.
CD8+ T lymphocytes of African green monkeys secrete an immunodeficiency virus-suppressing lymphokine.
Proc. Natl. Acad. Sci. USA
91:7207-7211 |
| 9. | Gomez, A. M., F. M. Smaill, and K. L. Rosenthal. 1994. Inhibition of HIV replication by CD8+ T cells correlates with CD4 counts and clinical stage of disease. Clin. Exp. Immunol. 97:68-75[Medline]. |
| 10. | Hoffman, A. D., B. Banapour, and J. A. Levy. 1985. Characterization of the AIDS-associated retrovirus reverse transcriptase and optimal conditions for its detection in virions. Virology 147:326-335[Medline]. |
| 11. | Hopkins, K. A. 1990. Basic lymphocytotoxicity test, p. 201. In A. Zachary, and G. A. Teresi (ed.), ASHI laboratory manual, 2nd ed., vol. 195. American Society for Histocompatibility and Immunogenetics, Lenexa, Kans. |
| 12. | Johnson, R. P., and B. Walker. 1994. Cytotoxic T lymphocytes in HIV infection: responses to structural proteins. Curr. Opin. Microbiol. Immunol. 189:35-63. |
| 13. | Kannagi, M., L. V. Chalifoux, C. I. Lord, and N. L. Letvin. 1988. Suppression of simian immunodeficiency virus replication in vitro by CD8+ lymphocytes. J. Immunol. 140:2237-2242[Abstract]. |
| 14. |
Kinter, A. L.,
S. M. Bende,
E. C. Hardy,
R. Jackson, and A. S. Fauci.
1995.
Interleukin 2 induces CD8+ T cell-mediated suppression of human immunodeficiency virus replication in CD4+ T cells and this effect overrides its ability to stimulate virus expression.
Proc. Natl. Acad. Sci. USA
92:10985-10989 |
| 15. | Landay, A. L., C. Mackewicz, and J. A. Levy. 1993. An activated CD8+ T cell phenotype correlates with anti-HIV activity and asymptomatic clinical status. Clin. Immunol. Immunopathol. 69:106-116[Medline]. |
| 16. | Levy, J. A., C. E. Mackewicz, and E. Barker. 1996. Controlling HIV pathogenesis: the role of noncytotoxic anti-HIV activity of CD8+ cells. Immunol. Today 17:217-224[Medline]. |
| 17. | Mackewicz, C., and J. A. Levy. 1992. CD8+ cell anti-HIV activity: nonlytic suppression of virus replication. AIDS Res. Hum. Retroviruses 8:1039-1050[Medline]. |
| 18. |
Mackewicz, C. E.,
E. Barker,
G. Greco,
G. Reyes-Teran, and J. A. Levy.
1997.
Do -chemokines have clinical relevance in HIV infection?
J. Clin. Investig.
100:921-930[Medline].
|
| 19. |
Mackewicz, C. E.,
D. J. Blackbourn, and J. A. Levy.
1995.
CD8+ cells suppress human immunodeficiency virus replication by inhibiting viral transcription.
Proc. Natl. Acad. Sci. USA
92:2308-2312 |
| 20. | Mackewicz, C. E., H. W. Ortega, and J. A. Levy. 1991. CD8+ cell anti-HIV activity correlates with the clinical state of the infected individual. J. Clin. Investig. 87:1462-1466. |
| 20a. | Mackewicz, C. E., H. Ortega, and J. A. Levy. 1994. Effect of cytokines on HIV replication in CD4+ lymphocytes: lack of identity with the CD8+ cell antiviral factor. Cell. Immunol. 153:329-343[Medline]. |
| 21. | Olerup, O., and H. Zetterquist. 1992. HLA-DR typing by PCR amplification with sequence specific primers (PCR-SSP) in 2 hours. Tissue Antigens 39:225-236[Medline]. |
| 22. |
Paliard, X.,
A. Y. Lee, and C. M. Walker.
1996.
RANTES, MIP-1 and MIP-1 are not involved in the inhibition of HIV-1SF33 replication mediated by CD8+ T-cell clones.
AIDS
10:1317-1321[Medline].
|
| 23. | Powell, J. D., T. Yehuda-Cohen, F. Villinger, H. M. McClure, K. W. Sell, and A. Ahmed-Ansari. 1990. Inhibition of SIV-SMM replication in vitro by CD8+ cells from SIV/SMM infected seropositive clinically asymptomatic sooty mangabeys. J. Med. Primatol. 19:239-249[Medline]. |
| 24. | Sherman, L. A., and S. Chattopadhyay. 1993. The molecular basis of allorecognition. Annu. Rev. Immunol. 11:385-402[Medline]. |
| 25. | Tateno, M., and J. A. Levy. 1988. MT-4 plaque formation can distinguish cytopathic subtypes of the human immunodeficiency virus (HIV). Virology 167:299-301[Medline]. |
| 26. | Toso, J. F., C. H. Chen, J. R. Mohr, L. Piglia, C. Oei, G. Ferrari, M. L. Greenberg, and K. J. Weinhold. 1995. Oligoclonal CD8 lymphocytes from persons with asymptomatic human immunodeficiency virus (HIV) type 1 infection inhibit HIV-1 replication. J. Infect. Dis. 172:964-973[Medline]. |
| 27. |
Tsubota, H.,
C. I. Lord,
D. I. Watkins,
C. Morimoto, and N. L. Letvin.
1989.
A cytotoxic T lymphocyte inhibits acquired immunodeficiency syndrome virus replication in peripheral blood lymphocytes.
J. Exp. Med.
169:1421-1434 |
| 28. |
Walker, C. M.,
D. J. Moody,
D. P. Stites, and J. A. Levy.
1986.
CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication.
Science
234:1563-1566 |
| 29. | Walker, C. M., G. A. Thomson-Honnebier, F. C. Hsueh, A. L. Erickson, L.-Z. Pan, and J. A. Levy. 1991. CD8+ T cells from HIV-1-infected individuals inhibit acute infection by human and primate immunodeficiency viruses. Cell. Immunol. 137:420-428[Medline]. |
| 30. | Wiviott, L. D., C. M. Walker, and J. A. Levy. 1990. CD8+ lymphocytes suppress HIV production by autologous CD4+ cells without eliminating the infected cells from culture. Cell. Immunol. 128:628-634[Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|